MYC positive diffuse large B cell lymphoma and Burkitt lymphoma MedDRA version: 20.0 Level: HLT Classification code 10012819 Term: Diffuse large B-cell lymphomas System Organ Class: 100000004943 MedDRA version: 20.0 Level: HLT Classification code 10006596 Term: Burkitt's lymphomas System Organ Class: 100000004943
Conditions
Interventions
Trade Name: Revlimid 2,5 mg
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: LENALIDOMIDE
CAS Number: 191732-72-6
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration num
Sponsors
HOVON Foundation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. DLBCL or BCL-U, histologically confirmed according to the WHO classification 2008 with a MYC rearrangement as determined by FISH comprising: - single hit (SH MYC+ lymphoma, not fulfilling the criteria for Burkitt Lymphoma ) or - double hit lymphoma (DH) MYC+/BCL2+ or MYC+/BCL6+ or - triple hit lymphoma (TH) MYC+/BCL2+/BCL6+ 2. Age = 18 year 3. No prior treatment except - local radiation or short course (max 7 days) steroids (max 100 mg/day) - 1 course of R-CHOP in case MYC positivity became evident during first cycle of treatment 4. WHO performance status (PS) 0-3, status 4 only if disease related (see appendix C) 5. Ann Arbor stage II-IV 6. Measurable disease: on contract-enhanced CT scan at least 1 lesions/node with a long axis of >1.5 cm and a short axis of =1.0 cm 7. Negative pregnancy test at study entry 8. Patient is willing and able to adhere to the requirements of the lenalidomide Pregnancy Prevention Risk Management Program 9. Written informed consent 10. Patient is capable of giving informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 54 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 16
Exclusion criteria
Exclusion criteria: 1. All histopathological diagnoses other than DLBCL not otherwise specified or BCL-U according to the WHO classification 2008 (like Burkitt Lymphoma, DLBCL associated with chronic inflammation) irrespective of the presence of MYC rearrangement 2. Known history of indolent lymphoma, or presence of indolent lymphoma in the diagnostic lymph node. If during screening localization of an indolent lymphoma in the bone marrow biopsy is diagnosed, the patient is eligible. 3. Absence of contract-enhanced CT scan (neck, thorax, abdomen, pelvis) and 18F-FDG PET scan before first cycle of R-CHOP 4. Inadequate renal function or creatinine clearance 3 times ULN (total) except patients with Gilbert's syndrome as defined by > 80% unconjugated bilirubin 6. Inadequate hematological function: ANC < 1.0x109/L or platelets < 75x109 /L unless lymphoma related 7. CNS localization of the lymphoma. Liquor analysis before start of treatment is only necessary in case of suspicion 8. Female subject pregnant or breast-feeding 9. History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma 10. Active symptomatic ischemic heart disease, myocardial infarction, or congestive heart failure within the past year. If echo or MUGA is obtained the LVEF should exceed 40% 11. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, cancer, etc.) that would jeopardize the patient's ability to receive the regimen with reasonable safety 12. HIV positivity 13. Active Hepatitis B or C infection as defined by positive serology and transaminitis. Non-active Hepatitis B carriers may be included if protected with lamivudine 14. Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D) 15. Severe neurological or psychiatric disease 16. Current participation in another clinical trial interfering with this trial 17. Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule 17. Claustrophobia to the extent that PET-CT is impossible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy of the combination of lenalidomide and R-CHOP in MYC+ DLBCL patients in terms of CR rate by end-of-treatment 18F-FDG PET-CT scan and BM.;Secondary Objective: - To evaluate the efficacy of the addition of lenalidomide to R-CHOP for MYC+ DLBCL patients in terms of EFS, DFS and OS . - To evaluate the value of mid-treatment 18F-FDG PET-CT scanning in predicting end-of-treatment 18F-FDG PET-CT result.;Primary end point(s): Complete remission rate as determined by - end-of-treatment PET-CT scan - negative bone marrow examination in case of localization of DLBCL or BLC-U at diagnosis;Timepoint(s) of evaluation of this end point: As soon as all data regarding end-of-treatment PET-CT and BM examinations for all eligible patients are available and have been validated. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - Event Free Survival (EFS) , defined as time from registration until no CR on protocol, relapse or death from any cause, whichever comes first - Overall survival (OS), calculated from registration until death from any cause Patients still alive or lost to follow up are censored at the last date known to be alive. - Disease free survival (DFS) from time of complete remission. DFS is defined as duration from start of CR to relapse or death from any cause, whichever comes first, and applies only to patients who achieved CR. - The relationship between mid-treatment 18F-FDG PET-CT result and end-of-treatment 18F-FDG PET-CT result.;Timepoint(s) of evaluation of this end point: Additional analyses will be performed at a later stage when the complete follow-up on the additional 5 years will be available for all patients. | — |
Countries
Belgium, Netherlands
Contacts
Public ContactHOVON Data Center
HOVON
Outcome results
None listed